Deslor Plus5 mg+240 mg

Deslor Plus is an established, approved combination indicated for the symptomatic relief of seasonal allergic rhinitis (hay fever) in patients whose symptoms include nasal congestion in addition to the classic antihistamine-responsive symptoms.

Established / approved use

• Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis — sneezing, rhinorrhea, itchy/watery eyes, itchy nose or throat — together with nasal congestion, in adults and adolescents 12 years of age and older.

Uses requiring the combination specifically

Deslor Plus is intended only for patients who have both allergy symptoms (addressed by the desloratadine component) and nasal congestion (addressed by the pseudoephedrine component). Patients with allergy symptoms but no congestion should use desloratadine alone, and patients with congestion only should use a decongestant alone.

Not established

Deslor Plus has not been shown to be effective for perennial (year-round) allergic rhinitis, the common cold, sinusitis, or non-allergic rhinitis, and is not indicated for children under 12 years of age.

Desloratadine + Pseudoephedrine is a fixed-dose combination of two active ingredients, typically formulated as a bilayer extended-release tablet:

• Desloratadine (commonly 2.5 mg or 5 mg per tablet) — an immediate-release, non-sedating second-generation antihistamine; it is the major active metabolite of loratadine.
• Pseudoephedrine sulfate (commonly 120 mg per tablet) — an extended-release oral nasal decongestant.

Exact strengths and release profile vary by manufacturer and by the specific product formulation; always check the packaging/prescribing information of the dispensed brand of Desloratadine + Pseudoephedrine for the precise composition.

Deslor Plus is an oral combination medicine that pairs a selective, non-sedating H1-antihistamine (desloratadine) with a sympathomimetic decongestant (pseudoephedrine). It is formulated to relieve both the allergic (sneezing, itching, runny nose) and congestive (stuffy nose) components of seasonal allergic rhinitis in a single tablet.

Deslor Plus is typically supplied as an extended-release tablet designed to be taken twice daily, with the antihistamine component released promptly and the decongestant component released over several hours.

Antihistamine–Decongestant combination (non-sedating H1-antihistamine plus sympathomimetic nasal decongestant); Deslor Plus belongs to the class of anti-allergic preparations used for allergic rhinitis with congestion.

Mechanism

Desloratadine + Pseudoephedrine combines two complementary mechanisms:

• Desloratadine is a long-acting, selective peripheral H1-receptor antagonist. By blocking histamine H1 receptors, it reduces sneezing, itching, rhinorrhea, and ocular symptoms triggered by histamine release during allergic reactions, without significant central sedative activity at recommended doses.
• Pseudoephedrine is an indirect-acting sympathomimetic amine. It stimulates alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction of dilated blood vessels, which reduces mucosal edema and nasal congestion.

Pharmacokinetics

Desloratadine is well absorbed orally, extensively metabolized, and has a plasma half-life of approximately 27 hours, supporting once- or twice-daily dosing depending on formulation. Pseudoephedrine is well absorbed, partly metabolized hepatically, and excreted largely unchanged by the kidneys; the extended-release layer of Desloratadine + Pseudoephedrine prolongs its absorption to support twice-daily dosing.

Take Deslor Plus tablets by mouth, swallowed whole with water, with or without food. Do not crush, break, or chew the tablet, as it is designed for extended release. Space doses approximately 12 hours apart.

The following interactions with Deslor Plus are well-documented and clinically significant:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, with Deslor Plus is contraindicated because the pseudoephedrine component can precipitate a hypertensive crisis.
• Other sympathomimetics (e.g., decongestants, appetite suppressants, stimulants): Combining these with Deslor Plus increases the risk of additive cardiovascular stimulation (increased blood pressure, arrhythmias).
• Antihypertensive agents and beta-blockers: The pseudoephedrine component of Deslor Plus may reduce the antihypertensive effect of these medicines and increase cardiovascular stress.
• Digoxin and other cardiac glycosides: Pseudoephedrine in Deslor Plus may increase the risk of cardiac arrhythmia when combined with digoxin.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May increase plasma levels of desloratadine when co-administered with Deslor Plus; clinically important adverse effects have not been established, but caution is advised.
• Alcohol and CNS depressants: Although desloratadine is minimally sedating, caution is advised when Deslor Plus is combined with alcohol or sedatives, as individual sensitivity varies.

The most commonly reported side effects of Deslor Plus (occurring in roughly 2% or more of patients) include:

• Insomnia / difficulty sleeping
• Headache
• Dry mouth
• Fatigue and somnolence
• Dizziness
• Nausea
• Sore throat (pharyngitis)
• Decreased appetite

Less common but more serious effects can include palpitations, tachycardia, elevated blood pressure, tremor, nervousness, and, rarely, hypersensitivity reactions (rash, angioedema, difficulty breathing) — see Precautions and Warnings and Overdose Effects for related safety information.

Pregnancy: Adequate, well-controlled studies of Deslor Plus in pregnant women are limited. Deslor Plus should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus, particularly given the vasoconstrictive effects of the pseudoephedrine component. A physician should be consulted before use in pregnancy.

Lactation: Both desloratadine and pseudoephedrine pass into breast milk. Pseudoephedrine may also reduce milk production/supply in some breastfeeding mothers. Deslor Plus should be used during breastfeeding only after consulting a physician, who can weigh the benefits against the potential risk to the nursing infant.

Deslor Plus should be used with caution in the following situations because of the sympathomimetic (pseudoephedrine) component:

• Cardiovascular disease, including hypertension, coronary artery disease, or arrhythmia (use only under medical supervision; see Contraindications for severe forms).
• Diabetes mellitus, as sympathomimetics can affect blood glucose control.
• Hyperthyroidism, since sympathomimetics may worsen thyrotoxic symptoms.
• Benign prostatic hyperplasia (BPH) or predisposition to urinary retention.
• Increased intraocular pressure or susceptibility to angle-closure glaucoma.

Hepatic or renal impairment: because Deslor Plus is a fixed-dose tablet, patients with significant hepatic or renal impairment who would otherwise need a reduced desloratadine dose should generally not use Deslor Plus; the individual components dosed separately are preferred so doses can be adjusted (see Use in Special Populations).

Deslor Plus may cause insomnia or, less commonly, drowsiness; patients should assess their own response before driving or operating machinery. Avoid use with other decongestants or stimulant medicines unless directed by a physician.

Overdose of Deslor Plus is expected to primarily produce effects related to excess sympathomimetic (pseudoephedrine) stimulation, potentially including rapid or irregular heartbeat, markedly elevated blood pressure, severe restlessness, tremor, anxiety, hallucinations, seizures, and, in severe cases, cardiovascular collapse. Antihistamine overdose effects such as marked drowsiness (in children, occasionally paradoxical excitation) may also occur.

If an overdose of Deslor Plus is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt specific home treatment; management should be supervised by medical professionals and may include supportive care and monitoring.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Elderly patients may be more sensitive to the sympathomimetic effects of the pseudoephedrine component of Deslor Plus, including effects on blood pressure, heart rhythm, and urinary retention (especially with coexisting BPH). Use Deslor Plus with caution and under medical supervision in this population.

Hepatic impairment

Desloratadine clearance may be reduced in hepatic impairment. Because the fixed combination does not allow dose adjustment, Deslor Plus is generally not recommended in patients with significant hepatic impairment; individual components dosed separately, under medical guidance, are preferred.

Renal impairment

Similarly, desloratadine clearance may be reduced in significant renal impairment. Deslor Plus is generally not recommended in this setting for the same reason; a physician should assess whether the individual components can be used with appropriate dose adjustment instead.

Pediatric population

Deslor Plus is not recommended for children under 12 years of age — safety and efficacy have not been established in this age group (see Pediatric Uses).

Deslor Plus is generally used for as long as seasonal allergic symptoms with nasal congestion persist, typically for the duration of the relevant pollen/allergy season. It is not intended for long-term continuous use without periodic medical review; if symptoms persist beyond a few weeks or worsen, a physician should reassess the diagnosis and treatment plan.

Desloratadine + Pseudoephedrine belongs to the Antihistamine (second-generation, non-sedating H1-receptor antagonist) drug class combined with a Decongestant (sympathomimetic amine) drug class.

Desloratadine + Pseudoephedrine works through two complementary actions: the desloratadine component selectively blocks peripheral histamine H1-receptors to relieve sneezing, itching, and rhinorrhea, while the pseudoephedrine component stimulates alpha-adrenergic receptors in nasal blood vessels to cause vasoconstriction, shrinking swollen nasal mucosa and relieving congestion.

C

Deslor Plus is not indicated for use in children under 12 years of age; safety and efficacy in this age group have not been established. In adolescents 12 years of age and older, the same adult dose (one tablet twice daily) is used. Parents/caregivers should consult a physician before giving any decongestant-containing product to a child, and Deslor Plus should never be given to infants or young children.